Delgocitinib

Delgocitinib
Clinical data
Trade namesCorectim
Other namesJTE-052; JTE-052A
ATC code
  • None
Legal status
Legal status
  • Rx-only in Japan
Identifiers
IUPAC name
  • 3-[(3S,4R)-3-Methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC16H18N6O
Molar mass310.361 g·mol−1
3D model (JSmol)
SMILES
  • C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
InChI
  • InChI=1S/C16H18N6O/c1-11-8-22(13(23)2-5-17)16(11)4-7-21(9-16)15-12-3-6-18-14(12)19-10-20-15/h3,6,10-11H,2,4,7-9H2,1H3,(H,18,19,20)/t11-,16-/m0/s1
  • Key:LOWWYYZBZNSPDT-ZBEGNZNMSA-N

Delgocitinib (brand name Corectim) is a pharmaceutical drug for the treatment of autoimmune disorders and hypersensitivity, including inflammatory skin conditions.[1] Delgocitinib was developed by Japan Tobacco and approved in Japan for the treatment of atopic dermatitis.[1] In the United States, delgocitinib is in Phase III clinical trials and the Food and Drug Administration has granted delgocitinib Fast Track designation for topical treatment of adults with moderate to severe chronic hand eczema.[2]

Delgocitinib works by blocking activation of the JAK-STAT signaling pathway which contributes to the pathogenesis of chronic inflammatory skin diseases.[3]

References

  1. 1 2 Dhillon S (April 2020). "Delgocitinib: First Approval". Drugs. 80 (6): 609–615. doi:10.1007/s40265-020-01291-2. PMID 32166597. S2CID 212681247.
  2. ↑ Park B (August 5, 2020). "Delgocitinib Cream Gets Fast Track Status for Chronic Hand Eczema". empr.com.
  3. ↑ Szalus K, Trzeciak M, Nowicki RJ (November 2020). "JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results". Microorganisms. 8 (11): 1743. doi:10.3390/microorganisms8111743. PMC 7694787. PMID 33172122.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.